Since 2001, GLEEVEC has been available for patients.
GLEEVEC is supported by clinical trial data backed by more than two decades of clinical use.1 First approved by the US Food and Drug Administration in 2001,1 the figures speak for themselves:
Over 15,000 published articles2
Over 740 clinical trials3
Over 5,000,000 packs distributed4
GLEEVEC has a well-established safety profile.
Thank you for trusting in GLEEVEC.
GLEEVEC BLISTER PACKAGING INSTRUCTIONAL VIDEO
SHELLPAK is a registered trademark of Westrock MWV, LLC.
UNIVERSAL CO-PAY PROGRAM
Patients may be eligible for immediate co-pay savings on their next prescription of GLEEVEC.
Eligible patients with private insurance may pay $10 per month
Novartis will pay the remaining co-pay, up to $30,000 per calendar year*
Encourage your patients to find out if they are eligible to enroll in the Universal Co-pay Program by visiting Copay.NovartisOncology.com or calling 1-877-577-7756.
*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program, or for Massachusetts patients or for California patients that do not meet additional eligibility criteria. Patient pays first $10 co-pay on a 30-day supply, and the program will pay up to $10,630 per 30-day supply up to an annual maximum of $30,000. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit Copay.NovartisOncology.com or call 1-877-577-7756.
Patient Assistance Now Oncology (PANO)
PANO is a support center consisting of insurance specialists and case managers who provide access to information regarding an array of services. Consider PANO your first stop for information about Novartis Oncology Patient support programs. Dedicated support specialists help direct callers to the services that best fit their needs.
To learn more, call 1-800-282-7630 or visit Novartis Patient Support.